VENETOCLAX DOSING AND DISPENSING GUIDE



This is a medical resource for scientific information and is intended for healthcare providers practicing in the United States.

Current as of February 2026

Genentech
A Member of the Roche Group

M-US-00023925 (v2.0)

DISCLAIMER SLIDE

Please Note: The information we provide may include references to a Genentech product or use of a Genentech product that the FDA has not approved; because the FDA has not approved such product(s) or use, no conclusions regarding safety or efficacy may be made. Providing this information should not be construed as recommendation for use of a Genentech product for unapproved uses. For FDA approved products please consult the product's full prescribing information for a complete discussion of risks and benefits of the product(s) for its approved indication(s).

The information we provide may additionally include relevant references to non-Genentech product information derived from publicly available sources.

This deck may contain animations; please review this slide deck in "slideshow" mode to ensure fair-balance display of content.

INDICATIONS AND RECOMMENDED DOSAGE FOR CLL

CLL/SLL

INDICATIONS AND USAGE

Venetoclax is a BCL-2 inhibitor indicated:

For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

In combination with obinutuzumab or acalabrutinib for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL)

In combination with rituximab for the treatment of adult patients with CLL who have received at least one prior therapy

RECOMMENDED DOSAGE

- The starting dose of VEN is 20mg QD for 7 days. The dose is then gradually increased over a period of 5 weeks to the recommended daily dose of 400 mg
- Acalabrutinib* is started on Cycle 1 Day 1 and is continued for a total of 14 cycles or until disease progression or unacceptable toxicity
- Obinutuzumab is started on Cycle 1 Day 1 and is continued for 6 cycles
- Rituximab is started after the patient has completed the 5-week dose ramp up with VEN and has received the 400mg dose of VEN for 7 days
- The 5-week ramp-up schedule is designed to gradually reduce tumor burden (debulk) and decrease the risk of TLS



*See product's full prescribing information for additional details on acalabrutinib. QD, daily; VEN, venetoclax.
Venclexta Prescribing Information, February 2026.

INDICATIONS AND RECOMMENDED DOSAGE FOR AML

AML

INDICATIONS AND USAGE

Venetoclax is a BCL-2 inhibitor indicated:

In combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults:

- 75 years or older, or
- who have comorbidities that preclude use of intensive induction chemotherapy

RECOMMENDED DOSAGE

- When combined with AZA or DEC, the VEN ramp-up is a 3-day daily increase to a final 400 mg QD



- When combined with LDAC, the VEN ramp-up is a 4-day daily increase to a final 600 mg QD

AZA, Azacitidine; DEC, decitabine; LDAC, low-dose cytarabine; QD, daily; VEN, venetoclax.

Venclexta Prescribing Information, February 2026.

M-US-00023925 (v2.0)

DOSING SCHEDULE TO GET TO STEADY-STATE DOSE OF 400MG/DAY FOR CLL

CLL/SLL

VEN+G in Previously Untreated CLL



- Start obinutuzumab administration on Cycle 1 Day 1 for a total of 6 cycles.
- Start the 5-week venetoclax ramp-up schedule on Cycle 1 Day 22.
- After completing the ramp-up phase on Cycle 2 Day 28, continue venetoclax at a dose of 400 mg PO QD from Cycle 3 Day 1 until the last day of Cycle 12.

VEN+R Relapsed/Refractory CLL



- Administer rituximab after the patient has completed the 5-week venetoclax ramp-up schedule.
- The recommended dose of venetoclax is 400 mg QD; venetoclax is taken for 24 months from Cycle 1 Day 1 of rituximab.

Monotherapy: The recommended dose of venetoclax is 400 mg QD. Treatment should be continued until disease progression or unacceptable toxicity.

CLL/SLL

VEN+A in Previously Untreated CLL

- Start acalabrutinib on Cycle 1 Day 1 PO approximately every 12 hours until disease progression, unacceptable toxicity or completion of 14 cycles of treatment. Each cycle is 28 days.
- Start the 5-week venetoclax ramp-up on Cycle 3 Day 1.
- After completing the ramp-up phase on Cycle 4 Day 7, continue venetoclax at a dose of 400 mg PO once daily until disease progression, unacceptable toxicity, or until the last day of Cycle 14.

CLL=Chronic Lymphocytic Leukemia. IV=Intravenous. PO=Orally. QD=Daily. SLL= small lymphocytic lymphoma.

Venclexta Prescribing Information, February 2026.

DOSING SCHEDULE TO GET TO STEADY-STATE DOSE FOR AML

AML

- The combination partner is initiated on day 1 of venetoclax dosing

VEN + AZA
VEN + DEC



Continue venetoclax, in combination with AZA or DEC, until disease progression or unacceptable toxicity.

AML

- The combination partner is initiated on day 1 of venetoclax dosing

VEN + LDAC



Continue venetoclax, in combination with LDAC, until disease progression or unacceptable toxicity.

AML=Acute Myeloid Leukemia. AZA=Azacitidine. DEC=Decitabine. IV=Intravenous. LDAC=low-dose cytarabine. PO=Orally. QD=Daily. SC=Subcutaneous. VEN=Venetoclax.

Venclexta Prescribing Information, February 2026.

M-US-00023925 (v2.0)

VENETOCLAX DOSE ADJUSTMENTS FOR ADVERSE EVENTS AND DRUG-DRUG INTERACTIONS

CLL/SLL

CLL Dosing Scenarios	Initiate/Ramp Up*	Steady-State (after ramp up)
CLL New Patient:	20mg, 50mg, 100mg, 200mg, 400mg	400mg
CLL Management: Adverse events	Variable	Variable (↓ dose)
CLL Drug Interactions:		
Posaconazole	X	70mg
Other strong CYP3Ai	X	100mg
Moderate CYP3Ai or P-gp inhibitor	↓50%	↓50% (e.g. 200mg or less)

* Ramp up, weekly (Weeks 1 – 5)

AML

AML Dosing Scenarios	Initiate/Ramp Up†	Steady-State (after ramp up)
AML New Patient:	100mg, 200mg, 400mg	400mg‡
AML Management: Adverse events	-	Variable – dependent on remission status
AML Drug Interactions:		
Posaconazole	10mg, 20mg, 50mg, 70mg	70mg
Other strong CYP3Ai	10mg, 20mg, 50mg, 100mg	100mg
Moderate CYP3Ai or P-gp inhibitor: VEN+ AZA/DEC	↓50%	↓50% (e.g. 200mg or less)

† VEN+HMA Ramp up, daily (Days 1 – 3)

‡If Venclexta used with LDAC, steady state dose is 600mg and ramp up is daily for 4 days. AML=Acute Myeloid Leukemia. AZA=azacitidine. CLL=Chronic Lymphocytic Leukemia. CYP3Ai=Cytochrome P450 3A4 inhibitor. DEC=decitabine. HMA= hypomethylating agent. LDAC=low-dose cytarabine. P-gp=p-glycoprotein. SLL=Small Lymphocytic Lymphoma. X=Contraindicated.

Venclexta Prescribing Information, February 2026.

STORE IN ORIGINAL CONTAINER AT OR BELOW 86°F (30°C). DISPENSE TO PATIENT IN ORIGINAL CONTAINER TO PROTECT FROM MOISTURE. ADVISE PATIENTS TO KEEP VENCLEXTA IN ORIGINAL CONTAINER.

Venetoclax is supplied as the following film-coated tablets

10 mg
Film coated tablets are round, biconvex shaped, pale yellow debossed with “V” on one side and “10” on the other side

50 mg
Film coated tablets are oblong, biconvex shaped, beige debossed with “V” on one side and “50” on the other side

100 mg
Film coated tablets are oblong, biconvex shaped, pale yellow debossed with “V” on one side and “100” on the other side

Venetoclax is supplied as the following packages

Dose-Escalation Starter Pack (CLL/SLL only)

Each pack contains 4 weekly wallet blister packs:

- Week 1 (14 × 10-mg tablets)
- Week 2 (7 × 50-mg tablets)
- Week 3 (7 × 100-mg tablets)
- Week 4 (14 × 100-mg tablets)

Bottles for Steady-State Dose

- 120 × 100-mg tablets
- 28 × 100-mg tablets

Wallets and Blister Packs for Replacement or Special Schedule Dosing

- Wallet: 14 × 10-mg
- Wallet: 7 × 50-mg
- Blister pack: 2 × 10-mg
- Blister pack: 1 × 50-mg
- Blister pack: 1 × 100-mg (unit dose)

VENCLEXTA Prescribing Information AbbVie Inc & Genentech Inc; June 2022. CLL=Chronic Lymphocytic Leukemia. SLL=Small Lymphocytic Lymphoma.
Venclexta Prescribing Information, February 2026.

DISPENSING VENETOCLAX: EXAMPLES OF CLINICAL SCENARIOS

Below are examples of dispensing scenarios by package size based on the venetoclax daily dose. Please refer to the Venclexta package insert for full dosing guidance.

 Dose-Escalation Starter Pack (CLL/SLL only)	• CLL New Patient Ramp Up
 120 count bottle (100mg)	• CLL Dose at Steady-State (400mg/day) • AML Dose at Steady-State (400mg/day)*
 28 count bottle (100mg)	• AML New Patient Ramp Up standard dose per PI • CLL / AML Management: Adverse events requiring dose holds or dose reductions • CLL / AML Drug Interactions: Steady-state venetoclax dose with a strong or moderate CYP3A inhibitor, or P-gp inhibitor
 Wallet & Blister Packs	• AML New Patient Ramp-up with dose reductions due to DDI's • CLL Therapy Restart: TLS reassessment • CLL / AML Management: Adverse events requiring dose holds or dose reductions • CLL / AML Drug Interactions: i.e. Posaconazole (70mg venetoclax dose) • CLL / AML Quantity dispensed per prescription < 28 count

*If Venclexta is used with LDAC, steady state is 600mg/day. AML=Acute Myeloid Leukemia. CLL=Chronic Lymphocytic Leukemia. CYP3A=Cytochrome P450 3A4. DDI=Drug-drug interactions. P-gp=p-glycoprotein. PI=Prescribing Information. SLL=Small Lymphocytic Lymphoma.

Venclexta Prescribing Information, February 2026.

VENETOCLAX DISPENSING GUIDE*: QUANTITY BY DOSE, TREATMENT DURATION, AND PACKAGE SIZES

Venetoclax is supplied as the following film-coated tablets

10 mg
Film coated tablets are round, biconvex shaped, pale yellow debossed with “V” on one side and “10” on the other side

50 mg
Film coated tablets are oblong, biconvex shaped, beige debossed with “V” on one side and “50” on the other side

100 mg
Film coated tablets are oblong, biconvex shaped, pale yellow debossed with “V” on one side and “100” on the other side

Store in original container at or below 86°F (30°C). Dispense to patient in original container to protect from moisture. Advise patients to keep VENCLEXTA in original container.

Venetoclax Package Size Presentation		National Drug Code
Wallet:	14 x 10 mg tablets	0074-0561-14
	7 x 50 mg tablets	0074-0566-07
Unit Dose Blister:	2 x 10 mg tablets	0074-0561-11
	1 x 50 mg tablets	0074-0566-11
	1 x 100 mg tablets	0074-0576-11
Bottle:	28 x 100 mg tablets	0074-0576-30
	120 x 100 mg tablets	0074-0576-22
Starting Pack (for CLL/SLL ONLY)		0074-0579-28

Venetoclax Dose (Steady-State)	Treatment Duration	Quantity to Dispense	Package Size Quantity
70 mg 	7 Days	7 x 50 mg 14 x 10 mg	1 x 50 mg Wallet 1 x 10 mg Wallet
	14 Days	14 x 50 mg 28 x 10 mg	2 x 50 mg Wallet 2 x 10 mg Wallet
	21 Days	21 x 50 mg 42 x 10 mg	3 x 50 mg Wallet 3 x 10 mg Wallet
	28 Days	28 x 50 mg 56 x 10 mg	3 x 50 mg Wallet 3 x 10 mg Wallet
100 mg 	7 Days	7	7 x Unit Dose
	14 Days	14	14 x Unit Dose
	21 Days	21	21 x Unit Dose
	28 Days	28	1 x 28 Count Bottle
200 mg 	7 Days	14	14 Unit Dose
	14 Days	28	1 x 28 Count Bottle
	21 Days	42	42 Unit Dose OR 14 x Unit Dose + 1 x 28 Count Bottle
	28 Days	56	2 x 28 Count Bottle
300 mg 	7 Days	21	21 Unit Dose
	14 Days	42	42 Unit Dose OR 14 x Unit Dose + 1 x 28 Count Bottle
	21 Days	63	63 Unit Dose OR 7 x Unit Dose + 2 x 28 Count Bottle
	28 Days	84	3 x 28 Count Bottle
400 mg 	7 Days	28	1 x 28 Count Bottle
	14 Days	56	2 x 28 Count Bottle
	21 Days	84	3 x 28 Count Bottle
	28 Days	112	4 x 28 Count Bottle
	30 Days	120	1 x 120 Count Bottle

*Guide is not all inclusive of dosing scenarios Venclexta Prescribing Information, February 2026..

M-US-00023925 (v2.0)

THANK YOU